Why the study?
Does long-term sibutramine treatment affect cardiovascular outcomes in overweight and obese subjects with preexisting cardiovascular conditions?
Does long-term sibutramine treatment affect cardiovascular outcomes in overweight and obese subjects with preexisting cardiovascular conditions?
Long-term sibutramine treatment in overweight and obese patients with preexisting cardiovascular conditions increases the risk of nonfatal myocardial infarction and stroke.
Avoid sibutramine in overweight patients with cardiovascular disease; confirms harm on nonfatal events in this RCT.
Subjects with preexisting cardiovascular conditions who were receiving long-term sibutramine treatment had an increased risk of nonfatal myocardial infarction and nonfatal stroke but not of cardiovascular death or death from any cause. (Funded by Abbott; ClinicalTrials.gov number, NCT00234832.)
No takes yet. Share an insight, caveat, or question.
James et al. (2010) studied this question.